Published in Nat Biotechnol on May 01, 1998
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res (2012) 1.67
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res (2012) 1.29
Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother (2009) 1.28
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (2004) 1.07
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 1.02
Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett (2012) 0.98
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther (2008) 0.94
IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol (2011) 0.93
An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol (2011) 0.91
Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. J Biol Chem (2012) 0.88
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med (2010) 0.88
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm (2008) 0.87
Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol (2014) 0.87
New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One (2013) 0.86
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol (2014) 0.84
Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13. Hum Gene Ther Methods (2012) 0.83
Molecular targeting of intracellular compartments specifically in cancer cells. Genes Cancer (2010) 0.83
Multifarious determinants of cytokine receptor signaling specificity. Adv Immunol (2014) 0.83
Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther (2014) 0.82
A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol (2012) 0.78
Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells. Prostate (2010) 0.78
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem (2011) 0.77
Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother (2013) 0.76
Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs (2012) 0.75
Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel. Sci Rep (2015) 0.75
Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. Oncotarget (2017) 0.75
Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges. Biomed Res Int (2017) 0.75
IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget (2017) 0.75
Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science (1993) 4.63
Water supplementation in exclusively breastfed infants during summer in the tropics. Lancet (1991) 2.09
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res (1999) 1.84
cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem (1996) 1.68
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res (2000) 1.55
Ehretianone, a novel quinonoid xanthene from Ehretia buxifolia with antisnake venom activity. J Nat Prod (1996) 1.53
Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem (1995) 1.52
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res (1995) 1.50
Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med (1999) 1.48
Intralesional treatment of established murine primary renal tumor with interleukin-4: localized effect on primary tumor with no impact on metastases. J Urol (1995) 1.44
Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med (2000) 1.41
Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene (2008) 1.41
Interleukin-2 toxicity. J Clin Oncol (1991) 1.40
Superiority of acridine orange-stained buffy coat smears for diagnosis of partially treated neonatal septicemia. Acta Paediatr (1993) 1.39
Charter for care of children in hospitals. Indian Pediatr (1991) 1.37
Oral submucous fibrosis--treatment with hyalase. J Laryngol Otol (1985) 1.33
Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest (1993) 1.30
A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem (1995) 1.30
Perinatal mortality-incidence and effect of various maternal factors, Part I. Indian J Pediatr (1982) 1.28
Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res (2000) 1.26
IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol (1996) 1.26
Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial cell transformation. Exp Cell Res (1998) 1.24
Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med (1998) 1.21
Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem (1996) 1.21
Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol (1994) 1.19
The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol (1997) 1.15
Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol (1998) 1.15
Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer (2001) 1.09
Risk factors for fatal diarrhea in hospitalized children in India. J Pediatr Gastroenterol Nutr (1991) 1.08
Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol (2000) 1.08
Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun (1997) 1.06
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res (1997) 1.06
IL-10 inhibits HIV-1 replication and is induced by tat. Biochem Biophys Res Commun (1994) 1.04
Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood (1998) 1.04
In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res (2001) 1.02
Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res (1996) 1.02
Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst (1988) 1.01
Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J Biol Chem (1995) 1.00
Polypeptide components of two 8 S forms of chicken oviduct progesterone receptor. J Biol Chem (1984) 1.00
Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol (1999) 0.99
Isolation of steroid receptor binding protein from chicken oviduct and production of monoclonal antibodies. Biochemistry (1985) 0.99
Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol (2004) 0.99
Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl (2003) 0.98
Phosphorylation in vivo of chicken oviduct progesterone receptor. J Biol Chem (1982) 0.98
Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res (2001) 0.98
An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer (1991) 0.97
A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci U S A (1994) 0.96
A profile of pyogenic meningitis in children. J Indian Med Assoc (1991) 0.96
Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system. Int J Hematol (1999) 0.96
VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol Med (2001) 0.95
Microbial transformation of primaquine by Candida tropicalis. Appl Environ Microbiol (1984) 0.95
Simple predictors to differentiate acute asthma from ARI in children: implications for refining case management in the ARI Control Programme. Indian Pediatr (1994) 0.94
Rectal histopathology in endemic Shigella and Salmonella diarrhea. J Pediatr Gastroenterol Nutr (1993) 0.94
Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol (2001) 0.93
In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med (2001) 0.93
Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain. Hum Gene Ther (2000) 0.93
A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J Biol Chem (1993) 0.91
Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med (2000) 0.90
IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice. J Immunol (2001) 0.89
Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res (1995) 0.89
Multiple structural domains within I kappa B alpha are required for its inducible degradation by both cytokines and phosphatase inhibitors. Biochem Biophys Res Commun (1996) 0.89
Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain. J Biol Chem (2001) 0.89
Exchange transfusion in neutropenic septicemic neonates: effect on granulocyte functions. Acta Paediatr (1993) 0.88
Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res (2000) 0.88
Infant feeding and child rearing methods in Pondicherry, South India. Indian J Pediatr (1976) 0.88
Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res (2001) 0.88
Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res (1998) 0.87
Childhood morbidity and mortality in a large hospital over last four decades. Indian Pediatr (1991) 0.87
Circularly permuted interleukin 4 retains proliferative and binding activity. Cytokine (1995) 0.87
Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood (2000) 0.87
Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model. Cell Immunol (1995) 0.87
Childhood diarrhoea and its association with enteropathogenic Esch. coli. Indian J Pediatr (1977) 0.87
Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo. Gene Ther (2003) 0.86
Serum enzyme abnormalities in protein energy malnutrition. Indian Pediatr (1993) 0.86
Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution. J Biol Chem (2000) 0.85
Poliomyelitis: 20 years--the Pondicherry experience. J Trop Med Hyg (1989) 0.85
Simpler tools for peritoneal dialysis of term newborns and young infants. Indian Pediatr (1994) 0.85
Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a. Cell Growth Differ (1997) 0.84
Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma. Clin Exp Immunol (1994) 0.84
Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer (1997) 0.83
Modulation of interleukin (IL)-13 binding and signaling by the gammac chain of the IL-2 receptor. J Biol Chem (1997) 0.82
Production of a novel dimeric metabolite of primaquine by Streptomyces rimosus. Appl Environ Microbiol (1984) 0.82
Purification of "nontransformed" avian progesterone receptor and preliminary characterization. J Biol Chem (1982) 0.82
Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther (2001) 0.82
Impact of national immunization schedule on vaccine preventable diseases: a hospital based study. Indian Pediatr (1992) 0.82